(Q36263659)

13 August 2017

1 reference

title

Update on anti-emetics for chemotherapy-induced emesis (English)

1 reference

13 August 2017

1 reference

Olver IN

1

1 reference

13 August 2017

publication date

1 August 2005

1 reference

Internal Medicine Journal

13 August 2017

published in

1 reference

13 August 2017

volume

35

1 reference

13 August 2017

issue

8

1 reference

13 August 2017

page(s)

478-481

1 reference

Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5004.2005.00879.X

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5004.2005.00879.X

Comparative studies of various antiemetic regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5004.2005.00879.X

Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5004.2005.00879.X

Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Instit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5004.2005.00879.X

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5004.2005.00879.X

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5004.2005.00879.X

Aprepitant in antiemetic combinations to prevent chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5004.2005.00879.X

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5004.2005.00879.X

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5004.2005.00879.X

Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5004.2005.00879.X

Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5004.2005.00879.X

Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5004.2005.00879.X

Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5004.2005.00879.X

Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5004.2005.00879.X

10.1111/J.1445-5004.2005.00879.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference